The transgenic NSG-Tg(Hu-IL15) mice express human IL15 and combined with the highly immunodeficient NOD scid gamma (NSG) mouse. Expression of human IL15 enhances the development of human NK cells in immunodeficient mice engrafted with human stem cells. This strain may be useful for studying immunotherapies targeting NK cells and NK cell function in tumorigenesis.
Dr. Leonard D. Shultz, The Jackson Laboratory
Contact Technical Support
|Allele Type||Gene Symbol||Gene Name|
|Spontaneous||Prkdc||protein kinase, DNA activated, catalytic polypeptide|
|Allele Type||Gene Symbol||Gene Name|
|Targeted (Null/Knockout)||Il2rg||interleukin 2 receptor, gamma chain|
|Transgenic (Inserted expressed sequence, Humanized sequence)|
NSG-Tg(Hu-IL15) mutant mice combine the features of the severe combined immune deficiency mutation or scid (B and T cell deficiency) and IL2 receptor gamma chain deficiency (NK cell deficiency) with expression of the human IL15 gene on the NOD/ShiLtJ background. Mice homozygous for the three mutations are viable, normal in size and do not display any gross physical or behavioral abnormalities; survival is similar to NSG mice. Hemizygous NSG-Tg(Hu-IL15) mice express a physiological level of human IL15 (7.1 +/- 0.3 pg/ml). Mice irradiated and injected with CD34+ human stems cells (HSC) develop significantly higher levels of functional human CD56+ NK cells in peripheral blood, spleen and bone marrow than NSG controls. This strain may be useful for studying immunotherapies targeting NK cells and NK cell function in tumorigenesis.
The transgenic construct consists of a 200 kbp human BAC RP11-620F30 containing the complete human IL15 (interleukin 15) gene. No other human genes are present in the BAC. The transgene was microinjected into fertilized NSG oocytes (Stock No. 005557: NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ). Founder mice were bred to NSG and the strain was thereafter maintained on the NSG background.
|Allele Name||severe combined immunodeficiency|
|Gene Symbol and Name||Prkdc, protein kinase, DNA activated, catalytic polypeptide|
|Site of Expression||T and B lymphocytes.|
|Strain of Origin||C.BKa-Ighb/Icr|
|Molecular Note||A T-to-A transversion point mutation at a position corresponding to codon 4046 (codon 4095 in transcript ENSMUST00000023352.8) created a premature stop codon (p.Y4046*).|
|Allele Name||targeted mutation 1, Warren J Leonard|
|Allele Type||Targeted (Null/Knockout)|
|Allele Synonym(s)||[KO]gammac; CD132-; gammac-; gc-; Il2rgtm1Wjll; IL2Rgammanull|
|Gene Symbol and Name||Il2rg, interleukin 2 receptor, gamma chain|
|Site of Expression||Primarily lymphoid cells.|
|Strain of Origin||129S4/SvJae|
|Molecular Note||A neomycin resistance cassette replaced part of exon 3 and all of exons 4 - 8 of the gene, resulting in the loss of most of the extracellular domain and all of the transmembrane and cytoplasmic domains of the protein.|
|Mutations Made By|| |
Dr. Warren Leonard, NHLBI, NIH
|Allele Name||transgene insertion 1, Leonard Shultz|
|Allele Type||Transgenic (Inserted expressed sequence, Humanized sequence)|
|Gene Symbol and Name||Tg(IL15)1Sz, transgene insertion 1, Leonard Shultz|
|Site of Expression||IL15 has widespread expression in a large number of cells and tissues.|
|Strain of Origin||NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ|
|Molecular Note||The transgenic construct consists of a 200 kbp human BAC RP11-620F30 containing the complete human IL15 (interleukin 15) gene. Mice express a physiological level of human IL15 (7.1 +/- 0.3 pg/ml).|
When maintaining a live colony, these mice are bred as homozygous for all three alleles (Il2rg is X-linked). Specific pathogen-free (SPF) conditions are recommended.
When using the NSG-Tg(Hu-IL15)
mouse strain in a publication, please cite the originating article(s) and include JAX stock #030890 in your Materials and Methods section.